Western blot results (Figures 5D,E) showed that at the cellular level and in mouse tumor tissues, gefitinib can induce STAT3 phosphorylation, while FMD inhibits gefitinib-induced STAT3 phosphorylation. The gene discussed is STAT3; the disease is neoplasm.